Annual Report 2001 - The Hospital for Sick Children

Stempak D, Dallas S, Klein J, Bendayan R,
Koren G, Baruchel S: Glutathione stability
in whole blood: Effects of various
deproteinizing acids. Therapeutic Drug
Monitoring: 2001: 23: 542-549.
Taddio A, Gurguis MG, Koren G: Lidocaine-
Prilocaine cream versus tetracaine gel for
procedural pain in children. Annals of
Pharmacotherapy: 2001: 36: 687-692.
Till C, Koren G, Rovet JF: Prenatal exposure
to organic solvents and child
neurobehavioral performance.
Neurotoxicology Teratology: 2001: 23:
235-245.
Till C, Westall CA, Rovet JF, Koren G:
Effects of maternal occupational exposure
to organic solvents on offspring visual
functioning: A prospective controlled
study. Teratology: 2001: 64: 134-141.
Ursitti F, Klein J, Koren G: Confirmation of
cocaine use during pregnancy: a critical
review. Therapeutic Drug Monitoring:
2001: 23: 347-353.
Ursitti F, Klein J, Sellers E, Koren G: Use of
hair analysis for confirmation of selfreported
cocaine use in users with
negative urine tests. Journal of
Toxicology, Clinical Toxicology: 2001: 39:
361-366.
Vohra S, Koren G: Hypothetical framework
for a relationship between maternal
thyroid function nausea and vomiting of
pregnancy, and congenital heart disease.
Medical Hypotheses: 2001: 56: 392-394.
Wong M, Koren G: Bias in maternal reports
of smoking during pregnancy associated
with fetal distress. Canadian Journal of
Public Health: 2001: 92: 109-112.
books and book chapters
Taddio A, Ito S: Drug use during lactation-a
review. In: G. Koren, ed. Maternal Fetal
Toxicology: a clinician’s guide. Marcel
Dekker, NY, 3rd ed. p177-232, 2001
Ito S: Drug use during pregnancy and
lactation. In: Pediatric drug therapy
handbook. I. Yoshida ed. Chuugai
Publishing (Tokyo). First ed. 2001: 32-36
Ito S, A Massicotte. Compendium of
Pharmaceuticals and Specialties, 36th ed.
2001: L41-L43 (Drug Exposure during
Pregnancy)
Ito S, D Matsui. Compendium of
Pharmaceuticals and Specialties, 36th ed.
2001: L44-L46 (Drug Exposure during
lactation)
Koren G: Special aspects of perinatal and
pediatric pharmacology. In: Katzung BG,
ed: Basic & Clinical Pharmacology. Lange
Medical Books/McGraw-Hill. 8th Edition,
2001, NY.
Shilalukey K, Koren G: Special
considerations in pregnant women. In:
Clinical Toxicology, (Ford, Delaney, Ling,
Erikson, ed) pp. 101-110, 2001. WB
Saunders. Philadlphia.
Koren G: Maternal-Fetal Toxicology; A
Clinician’s Guide. Third Edition, Marcel
Dekker, new York, 2001.
research and investigations
Antioxidants in Fetal Alcohol
Syndrome. Brien J, Koren G, Rovet J and
Other: New Emerging Team Grant, CIHR
($1,250,000 2002 - 2007)
Breaking the Cycle Program.
Koren G: Health Canada ($3,740,000
1994 - 2005).
Depression during breastfeeding:
the health of the mother and
infant. Ito S: Physicians Services
Incorporated ($123,600 2002 - 2004).
Determinants of renal handling of
drugs during development. Koren G:
CIHR Grant MA 8544 ($1,600,000 1984 -
2004).
Determinants of women's decisionmaking
of antidepressants during
pregnancy. Koren G: Ontario Women's
Health Council ($138,900 2001 - 2003).
Errors in drug dosing in children.
Parshuram C, Koren G, Bohn D: Critical Care
Foundation ($50,000 2002 - 2003).
Evaluating safety and risk of
antiretroviral drug exposure
during pregnancy for infants born
to HIV positive women in Ontario.
King SM, Koren G: Ontario HIV Treatment
Network (NHTV) ($175,000 1999 -
2002).
Maternal occupational exposure
to organic solvents during
pregnancy and infant visual
processing. Koren G, Rovet J, Estall C:
Workplace Safety and Insurance Board's
Research Advisory Council ($252,000
2001 - 2004).
Mechanisms of drug transfer into
human milk [MT-13747: Renewed
in 1999]. Ito S: CIHR ($219,852 1999 -
2002).
Organic cation uptake in the
human mammary gland:- Validity
of MCF12A cell model. Ito S (Principle
investigator): Food and Drug
Administration (USA) ($37,500 2001-
2002)
Propylthiouracil use during
breastfeeding: The cost of
misinformation. Ito S (Principle
investigator): Canadian Foundation for
Women’s Health (The Duchensney Fund
for better use of drugs during
pregnancy and lactation) ($16,000
2002-2003)
The role of the placenta in the
fetal toxicology [MT-1797:
Renewed in 1999]. Koren G, Derewlany
L, Ito S (Co-Investigators): CIHR ($252,720
1999 - 2002).
The safety of ondansetron in
pregnancy. Koren G, Einarson A: Glaxo
SKB ($60,000 2001 - 2002).
The teratogenicity of aspirin in
humans. Meta analysis. Koren, G:
Pfizer ($120,000 2001 - 2002).
Treatment of morning sickness.
Koren G: Duchesnay, Laval Quebec
($240,000 1994 - 2002).
Use of biotechnological products
during pregnancy and lactation.
Koren G: Health Canada ($56,000 2001 -
2002).
17